Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published online Dec. 28 in Blood ...
Jan 4, 2024
0
0
Some patients with aggressive lymphomas face a rare but clinically challenging prognosis when their cancer spreads to the central nervous system (CNS) or relapses there.
Sep 14, 2023
0
1
A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS), led by Assistant Professor Anand Jeyasekharan, has discovered a unique combination of oncogenes ...
Jul 19, 2023
0
0
The search for new therapies to treat a rare type of non-Hodgkins lymphoma has had an unexpected success—identifying a potential molecular target to treat other related forms of lymphoma as well.
Mar 14, 2023
0
2
Patient-reported outcomes from individuals diagnosed with relapsed or refractory large B-cell lymphoma revealed that those who received axicabtagene ciloleucel (axi-cel) immunotherapy experienced higher quality of life than ...
Jan 4, 2023
0
10
People suffering from blood cancer often have a weak immune system, putting them at higher risk of falling seriously ill with COVID-19. Some cancer therapies, moreover, result in these patients forming few or no antibodies ...
Dec 22, 2022
3
21
Together with researchers from University Hospital Mainz, the University of Regensburg and the IRCM in Montreal (Canada), a research team from Friedrich Schiller University Jena has discovered a novel therapeutic approach ...
Sep 21, 2022
0
4
DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process can go awry in people ...
May 25, 2022
0
6
(HealthDay)—Night shift work may increase the risk for chronic lymphocytic leukemia (CLL), according to a study published online Jan. 13 in Occupational & Environmental Medicine.
Jan 25, 2022
0
0
(HealthDay)—For patients with refractory or relapsed large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) leads to improvements in event-free survival and response compared with standard care, according to a study published ...
Dec 21, 2021
0
37
